Bactiguard (BACTI-B.ST) today announced that the trauma license partnership agreement with Zimmer Biomet, a global leader in the orthopedic field, has been updated. The updated partnership with Zimmer Biomet will focus on the continued commercialization of the coated trauma nail system, ZNN Bactiguard, across the European markets, selected MEA markets and Japan. The partnership covers markets where sales have already commenced, are expected to be launched in near-term or where regulatory approvals are in place. Bactiguard regains the remaining global rights within trauma.

Going forward, Bactiguard will continue to receive royalties on actual net sales of ZNN Bactiguard. The new agreement no longer includes annual minimum royalties. Instead, Bactiguard will receive a quarterly fixed fee from Zimmer Biomet. On a yearly basis, the fixed fees represent no less than half of the minimum royalty amount in the previous global trauma agreement.

The updated agreement is valid as of today and will have no negative financial impact for 2025. Moreover, the updated agreement does not change Bactiguard's 2030 strategic and financial targets.

Christine Lind, CEO of Bactiguard comments, "We are happy to continue our close collaboration with one of the global leaders in orthopedics, Zimmer Biomet. Under this updated arrangement, we will continue to work together to ensure that the ZNN Bactiguard infection prevention solution is available to patients in need."